Cutaneous Mastocytosis Market Size, Share, Growth, and Regional Forecast, 2025 - 2032

The global cutaneous mastocytosis market size is valued at US$295.9 million in 2025 and is projected to reach US$368.7 million by 2032, growing at a CAGR of 3.2% between 2025 and 2032. Cutaneous mastocytosis is a rare disorder, most commonly identified in children under two, and is characterized by an abnormal buildup of mast cells in the skin and occasionally other organs.

Although no permanent cure exists, symptom relief can be achieved with medications such as antihistamines, proton pump inhibitors, and corticosteroids. Growing research investments by leading pharmaceutical companies aim to advance therapeutic options and improve long-term management. Rising awareness among caregivers and healthcare providers, along with increased adoption of symptomatic treatments, continues to support early diagnosis and drive overall market growth worldwide.

• Leading Region: North America dominates the global market with 40.1%, driven by strong clinical research, multiple FDA approvals, established dermatology referral networks, and favorable reimbursement, driving market dominance for rare mastocytosis therapies.
• Fastest-Growing Region: The Asia Pacific market is expected to grow rapidly, with a CAGR of 3.9% over the forecast period, fueled by rising diagnoses, expanded dermatology access, increased registry participation, improved drug availability, and regulatory support.
• Leading Drug Class: Antihistamines lead with 45.2% share, supported by affordability, broad symptom control, pediatric suitability, first-line prescribing habits, and widespread availability in both outpatient and hospital settings.
• Leading Route of Administration: Convenience, improved adherence, suitability for long-term therapy, outpatient prescribing, and diverse oral formulations drive oral route dominance across age groups.
• Increasing R&D Investments: Drug developers are accelerating the development of next-generation Tyrosine Kinase Inhibitors (TKIs) and precision therapies to address unmet needs in systemic and cutaneous mastocytosis.
• Expanding Clinical Guidelines: New national and regional mastocytosis guidelines are standardizing diagnosis and improving care pathways.
• Strengthening Orphan Drug Incentives: Regulatory support and market exclusivity for rare-disease therapies are attracting biopharma interest and boosting innovation in the management of mastocytosis.

Driver - Growing Awareness, Therapeutic Advancements, and Research Investments Accelerate Global Market Expansion

The global cutaneous mastocytosis market is gaining momentum, largely driven by rising awareness of the condition, its symptoms, and available treatment pathways. Greater understanding among parents—especially for infants—has increased early medical consultations, thereby strengthening diagnostic rates worldwide. Support from non-profit organizations and government bodies further amplifies education and awareness efforts, reinforcing long-term market growth.

Although no permanent cure exists, photochemotherapy (PUVA) remains a widely acknowledged and practiced approach that combines psoralens with long-wave ultraviolet radiation. Its consistent clinical outcomes and expanding adoption continue to position PUVA as a key therapeutic driver.

At the same time, increasing investments in research and drug development by leading industry players are accelerating innovation. Advancements in understanding disease pathogenesis, along with the development of novel diagnostic and prognostic tools, are improving therapeutic decision-making and enabling more precise management. Collectively, these factors are expected to create new opportunities for improved care and fuel steady global market expansion over the forecast period.

Restraints - High Treatment Costs and Safety Concerns Continue to Restrain Global Mastocytosis Market Growth

The global cutaneous mastocytosis market faces notable restraints, primarily driven by the high cost of treatment and supportive medications. Although photochemotherapy (PUVA) is gaining traction as an effective therapeutic option, it demands 10 to 15 sessions per month, making it financially inaccessible for many middle- and low-income patients. This cost burden significantly limits treatment uptake, despite increasing awareness and clinical acceptance.

In addition to affordability challenges, the adverse effects associated with several treatment drugs further hinder broader market adoption. Safety concerns often lead to delayed treatment initiation or discontinuation, reducing overall patient adherence. Together, these factors—elevated therapy costs, frequent treatment requirements, and potential side effects—remain major obstacles to sustained global market growth for therapies for cutaneous mastocytosis.

Opportunity - Advancing Targeted Therapies Creates Strong Opportunities

Growing innovation in targeted therapies is opening significant opportunities for the global cutaneous and systemic mastocytosis market. A key driver is the unmet need in systemic mastocytosis (SM), where mutations such as KIT D816V keep mast cells in a perpetual activation state, leading to multisystem disease. Cogent Biosciences’ bezuclastinib, a highly selective type I TKI, offers a major opportunity by potently inhibiting KIT D816V with minimal off-target activity, addressing long-standing limitations of older TKIs.

Momentum accelerated in July 2025, as new TKIs demonstrated promising outcomes in large SM trials. Updates from the HARBOR and SUMMIT studies at the 2025 AAAAI (American Academy of Allergy, Asthma & Immunology) Annual Meeting highlighted strong clinical activity, with SUMMIT delivering statistically significant top-line results for bezuclastinib. At the same time, Blueprint Medicines advanced its next-generation KIT D816V inhibitor elenestinib (BLU-263), now in a randomized Phase 2/3 HARBOR trial.

An additional opportunity lies in TL-895 (Telios Pharma), currently in Phase II for SM and multiple related hematologic disorders, targeting BTK through an oral formulation. Collectively, these next-generation precision therapies are poised to expand treatment options and accelerate global market growth.

By Drug Class: Antihistamines Dominate Owing to Broad Symptom Control and High First-Line Preference

Antihistamines are expected to capture 45.2% of the global cutaneous mastocytosis market by 2025, driven by their widespread use as the primary symptomatic treatment for pruritus, flushing, and dermatologic flare-ups. Their affordability, broad availability across regions, and established safety profile make them the most accessible first-line option for both adult and pediatric patients. Continued physician reliance on H1 and H2 blockers, combined with rising diagnosis rates and guideline-based management protocols, further strengthens their market leadership.

By Route of Administration: Oral Route Lead Due to Convenience, Better Compliance, and Wider Patient Acceptance

The oral route is projected to dominate the market in 2025 with a 61.7% share, supported by its convenience, non-invasive nature, and suitability for long-term management. Oral antihistamines, cromolyn sodium, and supportive therapies are commonly prescribed for chronic symptom control, driving higher adoption. This route also enables easier dosing adjustments, improves adherence, and is preferred in outpatient and pediatric care settings. Growing availability of oral formulations and expanding prescription volume further solidify its leading position in the treatment of cutaneous mastocytosis.

By Distribution Channel: Hospital Pharmacies Lead Due to Specialist Access and Higher Prescription Volumes

Hospital pharmacies are set to capture 57.2% of the market in 2025, driven by the concentration of dermatologists, allergists, and immunologists within hospital settings where most cutaneous mastocytosis cases are evaluated. Complex cases requiring diagnostic support or combination therapy often originate in hospitals, increasing prescription volume through this channel. Hospital pharmacies also maintain reliable access to specialty medications, ensure proper therapeutic guidance, and support continuation of care for both acute flares and chronic management, reinforcing their dominant market share.

North America Cutaneous Mastocytosis Market Trends

By 2025, North America is projected to account for nearly 40.1% of the global cutaneous mastocytosis market, supported by a strong clinical research ecosystem for rare dermatological disorders and higher awareness that enables earlier identification through established dermatology networks.

Despite this progress, systemic mastocytosis (SM), a closely linked rare condition affecting around 32,000 individuals in the United States, continues to be underdiagnosed due to nonspecific presentations and the need for invasive biopsies. This growing recognition gap is accelerating demand for improved diagnostic pathways and specialized care. In June 2023, the U.S. FDA approved AYVAKIT® (avapritinib) for indolent systemic mastocytosis (ISM), marking the first targeted therapy for the most common SM subtype.

Historically, ISM management relied primarily on symptomatic control due to limited therapeutic options. The approval reflects increasing regulatory momentum and validates the region’s robust trial infrastructure. Companies, including ARUP Laboratories, played a pivotal role by supporting the PIONEER clinical trial from early stages, providing centralized pathology review to confirm patient eligibility and assess treatment response.

Together, rising diagnostic capability, expanding therapeutic innovation, and strong clinical-trial support systems continue to shape North America as the leading growth engine for the cutaneous mastocytosis market.

Europe Cutaneous Mastocytosis Market Trends

By 2025, Europe is expected to capture 21.7% of the global cutaneous mastocytosis market, supported by robust rare-disease regulatory frameworks, incentives, and the expanding adoption of guideline-based management protocols. The region’s strong regulatory environment continues to encourage innovation, accelerate approvals, and strengthen access to rare-disease therapies.

A major growth catalyst emerged in July 2025, when Sanofi completed its acquisition of Blueprint Medicines, adding a commercialized therapy, a strong clinical pipeline, and deep expertise in systemic mastocytosis (SM) and other KIT proto-oncogene receptor tyrosine kinase (KIT)-driven disorders.

The acquisition strengthens Sanofi’s presence across allergists, dermatologists, and immunologists. It brings Ayvakit/Ayvakyt (avapritinib)-the only approved treatment for both advanced and indolent systemic mastocytosis (ASM & ISM) in the US and EU-into its portfolio. It also includes two key pipeline assets: elenestinib, a next-generation selective KIT D816V inhibitor evaluated in the Phase 2/3 HARBOR study, and BLU-808, a potent wild-type KIT inhibitor linked to broader inflammatory pathways.

Europe’s innovation landscape is further reinforced by companies including AB Science, which resumed patient enrollment in August 2021 for its confirmatory Phase 3 masitinib trial. In May 2024, a new European patent (EP 3359195A1) extended IP protection for masitinib in severe mastocytosis until 2036, complementing orphan drug designations granted by both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA). Together, these advancements continue to underpin Europe’s strong momentum in the cutaneous and systemic mastocytosis space.

Asia Pacific Cutaneous Mastocytosis Market Trends

The Asia Pacific cutaneous mastocytosis market is expanding steadily. It is projected to grow at a CAGR of 3.9%, supported by rising diagnostic rates, improved dermatology access, and increasing participation in patient registries, which enhance early detection. Growing adoption of both targeted and symptomatic therapies continues to strengthen clinical management across emerging and developed Asia Pacific healthcare systems.

A significant regional inflection point occurred in February 2023, when CStone Pharmaceuticals announced that avapritinib (AYVAKIT®) was included as a recommended treatment for advanced systemic mastocytosis (SM) in the first-ever Chinese Guidelines for the Diagnosis and Treatment of Systemic Mastocytosis in Adult Patients.

As a potent, selective inhibitor of KIT and PDGFRA mutant kinases, avapritinib represents an important advancement for SM care. CStone, holding exclusive development and commercialization rights across Mainland China, Hong Kong, Macau, and Taiwan, is positioned to expand access to advanced therapies in the region.

The new Chinese Guidelines, developed by leading hematology and mastocytosis experts, standardize diagnostic procedures, clarify differential diagnosis, define response criteria, and outline treatment pathways. Their publication is expected to improve diagnostic consistency, support innovation, and accelerate therapeutic adoption.

Collectively, enhanced clinical frameworks, expanding drug availability, and rising physician awareness are shaping the Asia Pacific into a high-potential growth market for cutaneous and systemic mastocytosis therapies.

The cutaneous mastocytosis market is shaped by strong R&D activity focused on advancing symptomatic and targeted therapies. Companies are increasingly investing in novel drug platforms, expanding clinical programs, and forming strategic collaborations with emerging innovators to enhance innovation, broaden portfolios, and accelerate the development of next-generation treatments.

Key Industry Developments:  

• In October 2025, the global community united for the eighth International Mastocytosis & Mast Cell Diseases Awareness Day under the theme “Be informed, Be connected. The campaign, supported by Blueprint Medicines and Cogent Biosciences, featured multilingual fact sheets, patient surveys with 1,000+ participants, translated resources, and the hashtag #LifeWithMastCellDisease to amplify shared stories and build solidarity.
• In May 2025, A new longitudinal registry (MaRe) in Italy started recruiting patients with cutaneous and systemic mastocytosis through IRCCS Fondazione Policlinico San Matteo, aiming to collect epidemiological, genetic, and molecular data from around 600 participants.